anti-integrin alphaV/beta8 monoclonal antibody CRB-601

A humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against integrin alphaV/beta8 (aVb8), with potential antineoplastic activity. Upon administration, anti-integrin aVb8 monoclonal antibody CRB-601 targets and binds to integrin aVb8. This prevents the binding of integrin aVb8 to latent human transforming growth factor (TGF)-beta (L-TGFb) and inhibits the activation of L-TGFb complexes, thereby preventing TGFb-mediated signaling. This abrogates TGFb-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFb-dependent proliferation of cancer cells. Integrin aVb8 plays a key role in tumor initiation, growth, and progression through TGF-b activation. It is expressed in a variety of tumor cell types and is associated with poor prognosis.